SELLAS Life Sciences Group, Inc. Effective Income Tax Rate Reconciliation, Other Adjustments, Percent
SELLAS Life Sciences Group, Inc. (SLS) reported Effective Income Tax Rate Reconciliation, Other Adjustments, Percent of 0.20% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-19.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments · last filed 2026-03-19
- SELLAS Life Sciences Group, Inc. effective income tax rate reconciliation, other adjustments, percent for fiscal 2025 was 0.20%, a 0.00% change from fiscal 2024.
- SELLAS Life Sciences Group, Inc. effective income tax rate reconciliation, other adjustments, percent for fiscal 2024 was 0.20%, a 75.00% decline from fiscal 2023.
- SELLAS Life Sciences Group, Inc. effective income tax rate reconciliation, other adjustments, percent for fiscal 2023 was 0.80%.
- SELLAS Life Sciences Group, Inc. effective income tax rate reconciliation, other adjustments, percent for fiscal 2022 was -0.30%.
| Period end | Effective Income Tax Rate Reconciliation, Other Adjustments, Percent 12 month | Effective Income Tax Rate Reconciliation, Other Adjustments, Percent 12 month as first filed |
|---|---|---|
| 2025-12-31 | 0.20% 10-K · filed 2026-03-19 | |
| 2024-12-31 | 0.20% 10-K · filed 2026-03-19 | |
| 2023-12-31 | 0.80% 10-K · filed 2025-03-20 | |
| 2022-12-31 | -0.30% 10-K · filed 2024-03-28 | |
| 2021-12-31 | -0.10% 10-K · filed 2023-03-16 | |
| 2020-12-31 | -11.00% 10-K · filed 2022-03-31 | |
| 2019-12-31 | -0.80% 10-K · filed 2021-03-23 | |
| 2018-12-31 | -0.10% 10-K · filed 2020-03-13 | |
| 2017-12-31 | -0.20% 10-K · filed 2019-03-22 | 0.20% 10-K · filed 2018-04-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |